| Literature DB >> 28874128 |
Qing-Jun Chu1, Rui Hua1, Chen Luo1, Qing-Jie Chen1, Biao Wu1, Song Quan2, Yong-Tong Zhu3.
Abstract
BACKGROUND: Chromosomal disorders in non obstructive azoospermia (NOA) may have an important influence on spermatogenesis, which may be reflected by the serum inhibin B levels. Till now, few studies have concerned the relationship of genetic causes and inhibin B in NOA.Entities:
Keywords: Inhibin B; Karyotype; Non obstruction azoospermia; Y chromosome microdeletion
Mesh:
Substances:
Year: 2017 PMID: 28874128 PMCID: PMC5585947 DOI: 10.1186/s12881-017-0456-x
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Primers of selected genes
| Gene name | Primers (forward/reverse) |
|---|---|
| SY133 | 5-ATTTCTCTGCCCTTCACCAG-3 |
| SY146 | 5-ACAAAAATGTGGCTCAGGGA-3 |
| SY153 | 5-GCATCCTCATTTTATGTCCA-3 |
| SY155 | 5-ATTTTGCCTTGCATTGCTAG-3 |
| SY157 | 5-CTTAGGAAAAAGTGAAGCCG-3 |
| SY158 | 5-CTCAGAAGTCCTCCTAATAGTTCC-3 |
| SY182 | 5-TCAGAAGTGAAACCCTGTATG-3 |
| SY238 | 5-AACAAGTGAGTTCCACAGGG-3 |
| SY254 | 5- GGGTGTTACCAGAAGGCAAA −3 |
| SY255 | 5-GTTACAGGATTCGGCGTGAT-3 |
| SY272 | 5-GGTGAGTCAAATTAGTCAATGTCC-3 |
| SY277 | 5-GGGTTTTGCCTGCATACGTAATTA-3 |
| SY283 | 5-CAGTGATACACTCGGACTTGTGTA-3 |
Fig. 1Serum inhibin B levels in different histopathological patients. Values represent the mean ± standard error. Significance between groups is indicated by *p < 0.05
Patient histopathological characteristics
| Biopsy | Non-biopsy | Overall | ||||
|---|---|---|---|---|---|---|
| Hypospermatogenesis | Maturation arrest | Sertoli cell only | ||||
| No | 169 | 64 | 45 | 44 | 322 | |
| Age (y) | 27.78 ± 3.26 | 27.40 ± 3.29 | 30.33 ± 4.05 | 29.67 ± 4.09 | 29.83 ± 4.54 | 0.65(a) |
| Testis volumn (ml) | 12.4 ± 4.3 | 10.7 ± 4.0 | 8.0 ± 1.4 | 1.5 ± 1.6 | 5.8 ± 5.4 | <0.05(a) |
| FSH (mIU/ml) | 8.01 ± 3.57 | 14.74 ± 3.57 | 34.02 ± 7.02 | 35.65 ± 6.61 | 18.02 ± 7.16 | <0.05(a) |
| Free testosterone (pg/ml) | 9.81 ± 1.73 | 8.69 ± 2.68 | 5.62 ± 1.73 | 2.55 ± 2.03 | 6.04 ± 3.06 | <0.05(a) |
| Inhibin B (pg/ml) | 86.96 ± 40.97 | 39.72 ± 5.91 | 14.73 ± 2.23 | 10.71 ± 3.23 | 46.01 ± 43.17 | <0.05(a) |
| Abnormal karyotypes (%) | 26(8.0) | 23(7.1) | 21(6.5) | 42(13.0) | 112(34.8) | <0.05(b) |
| YCMD | 13(4.0) | 12(3.7) | 15(4.7) | 18(5.6) | 58(18.0) | <0.05(b) |
YCMD Y chromosome microdeletion
a:1-way ANOVA; b: chi-square test
Correlation between karyotypes and Y chromosome microdeletions
| karyotypes | ||||
|---|---|---|---|---|
| abnormal | normal | Total | ||
| YCMD | microdeletions | 32 | 26 | 58 |
| No deletion | 80 | 184 | 264 | |
| Total | 112 | 210 | 322 | |
χ2 = 11.892, continuity corrected P < 0.001
YCMD Y chromosome microdeletion
Abnormal karyotypes and inhibin B
| No | % | Inhibin B (pg/ml) | |
|---|---|---|---|
| 46,XY | 210 | 65.2 | 84.00 ± 38.16 |
| 47,XXY | 34 | 10.6 | 10.49 ± 3.81 |
| 46,XX or 45,X | 8 | 2.5 | 3.74 ± 1.43 |
| Mosaic karyotypes | 12 | 3.7 | 33.23 ± 25.68 |
| Polymorphism of sexual chromosome | 27 | 8.4 | 68.58 ± 70.37 |
| Chromosomal inversion | 10 | 3.1 | 111.14 ± 53.24 |
| Chromosomal translocation | 8 | 2.5 | 158.01 ± 62.34 |
| Abnormal karyotypes, otherwise | 13 | 4.0 | 96.43 ± 46.31 |
| Total | 322 | 100.0 | 84.01 ± 63.17 |
|
| <0.05 (1-way ANOVA) |
Fig. 2Serum inhibin B levels in different karyotypes patients. Values represent the mean ± standard error. Significance between groups is indicated by *p < 0.05
Y chromosome microdeletions and inhibin B
| No | % | Inhibin B (pg/ml) | ||||
|---|---|---|---|---|---|---|
| No deletion | 264 | 82.0 | 115.04 ± 89.30 | |||
| Non-AZF a&b | 35 | 10.9 | 86.34 ± 69.65 | |||
| AZF c | 12 | 3.7 | 93.37 ± 61.82 | |||
| AZF d | 3 | 0.9 | 82.17 ± 64.55 | |||
| AZF c + d | 20 | 6.2 | 89.98 ± 50.11 | |||
| AZF a&b | 23 | 7.1 | 38.80 ± 27.14 | |||
| AZF a | 2 | 0.6 | 16.05 ± 1.53 | |||
| AZF b | 6 | 1.9 | 56.16 ± 39.54 | |||
| AZF b + c | 5 | 1.6 | 19.86 ± 24.05 | |||
| AZF b + c + d | 2 | 0.6 | 28.89 ± 25.46 | |||
| AZF a + b + c + d | 8 | 2.5 | 10.14 ± 15.22 | |||
| Total | 322 | 100.0 | 84.01 ± 63.17 | |||
|
| <0.05 (1-way ANOVA) | |||||
Fig. 3Serum inhibin B levels in (a) men with AZF a&b site Y chromosome microdeletions patients (YCMD), Non-AZF a&b site YCMD and no deletion and (b) different YCMD